Background. One of the current prophylactic interventions to prevent restenosis includes the use of immunosupressants. Marked activation of inflammatory cells at the site of stent plays a role in the process of restenosis. However, clinical trials in humans using prednisone, both oral and intravenous preparations still shows mixed results and needs to be reviewed.
Objectives. To assess the efficacy of prednisone on preventing coronary artery restenosis among patients who underwent percutaneous coronary intervention (PCI) using bare-metal stents.
Methods. This is a meta-analysis of randomized, double-blind, placebo-controlled clinical trials using prednisone or its steroid equivalent as intervention for preventing coronary artery restenosis and cardiovascular events among coronary artery disease patients who underwent PCI using bare-metal stents.
Results. Four studies were included in the meta-analysis. Risk ratio of restenosis rates was 0.83(95% CI 0.59-1.16). heterogeneity was moderate (I2=57%). Three studies reported a 12-month event-free survival rate. Prednisone had a risk ratio of 0.55 (95% CI 0.39-0.79); but heterogeneity was moderate.
To assess the efficacy of prednisone on preventing coronary artery restenosis among patients who underwent percutaneous coronary intervention (PCI) using bare-metal stents.